UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, aiming to accelerate the development of novel oncology candidates by ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

UCB UCB-5.35%decrease; down pointing triangle said it agreed to buy Candid Therapeutics for up to $2.2 billion, in a deal that seeks to bolster the Belgian pharmaceutical company’s pipeline of ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in late Q2/early Q3 2026 subject to antitrust clearance. Cizutamig is a BCMA×CD3 ...

The acquisition draws some similarities to UCB's agreement in 2022 to purchase epilepsy drugmaker Zogenix. (UCB) After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's ...

UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first plant in the U.S. for the Belgium-based company and will produce ...

UCB's fast-rising IL-17 Bimzelx has topped AbbVie's Skyrizi in a phase 3b study of patients with active psoriatic arthritis. () After strutting its stuff against blockbusters in three head-to-head ...

UCB Chief Scientific Officer Alistair Henry said T-cell engagers are “emerging as an exciting and potentially disruptive therapeutic modality for immunological diseases.” (iStock/Getty Images Plus) ...

Abstract: Mobile Edge Computing (MEC) is an emerging network architecture designed to enhance Quality of Service (QoS) by bringing computational resources and storage closer to end users. In MEC ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease. Roche has cut ...